Nutra Pharma Corp.
NPHC
$0.0003
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 465.80% | 196.39% | 0.91% | 71.05% | 44.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 465.80% | 196.39% | 0.91% | 71.05% | 44.03% |
| Cost of Revenue | 328.13% | 575.56% | 157.14% | 161.04% | 209.68% |
| Gross Profit | 610.42% | 37.67% | -52.44% | -302.06% | -6.80% |
| SG&A Expenses | -41.62% | -19.45% | -43.29% | 32.33% | 169.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.97% | -8.03% | -41.30% | 40.98% | 169.71% |
| Operating Income | 53.84% | 22.25% | 43.02% | -39.70% | -178.73% |
| Income Before Tax | -96.26% | -119.21% | 114.74% | 206.66% | 2,525.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.26% | -119.21% | 114.74% | 206.66% | 2,525.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.26% | -119.21% | 114.74% | 206.66% | 2,525.62% |
| EBIT | 53.84% | 22.25% | 43.02% | -39.70% | -178.73% |
| EBITDA | 54.74% | 23.24% | 43.85% | -39.39% | -179.03% |
| EPS Basic | -95.24% | -120.00% | 114.58% | 200.00% | 2,000.00% |
| Normalized Basic EPS | -100.00% | -100.00% | 113.33% | 166.67% | 1,200.00% |
| EPS Diluted | -100.00% | -150.00% | 106.25% | 200.00% | -- |
| Normalized Diluted EPS | -100.00% | -100.00% | 106.67% | 166.67% | -- |
| Average Basic Shares Outstanding | 4.16% | 3.04% | 4.05% | 6.30% | 9.78% |
| Average Diluted Shares Outstanding | 23.11% | -36.50% | 105.22% | 6.30% | -3.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |